Fintel reports that on April 20, 2023, EF Hutton reiterated coverage of Innoviva (NASDAQ:INVA) with a Buy recommendation.
Analyst Price Forecast Suggests 30.55% Upside
As of April 6, 2023, the average one-year price target for Innoviva is $15.47. The forecasts range from a low of $10.10 to a high of $23.62. The average price target represents an increase of 30.55% from its latest reported closing price of $11.85.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Innoviva is $277MM, a decrease of 16.51%. The projected annual non-GAAP EPS is $1.49.
What are Other Shareholders Doing?
NORTHWESTERN MUTUAL SERIES FUND INC – Index 600 Stock Portfolio holds 26K shares representing 0.04% ownership of the company. No change in the last quarter.
CSF – VictoryShares US Discovery Enhanced Volatility Wtd ETF holds 15K shares representing 0.02% ownership of the company. In it’s prior filing, the firm reported owning 3K shares, representing an increase of 79.33%. The firm increased its portfolio allocation in INVA by 366.62% over the last quarter.
DFAS – Dimensional U.S. Small Cap ETF holds 146K shares representing 0.21% ownership of the company. In it’s prior filing, the firm reported owning 128K shares, representing an increase of 12.21%. The firm decreased its portfolio allocation in INVA by 7.56% over the last quarter.
QCSTRX – Stock Account Class R1 holds 204K shares representing 0.30% ownership of the company. In it’s prior filing, the firm reported owning 310K shares, representing a decrease of 51.54%. The firm decreased its portfolio allocation in INVA by 30.19% over the last quarter.
DMVAX – BNY Mellon Select Managers Small Cap Value Fund holds 99K shares representing 0.15% ownership of the company.
What is the Fund Sentiment?
There are 516 funds or institutions reporting positions in Innoviva. This is a decrease of 9 owner(s) or 1.71% in the last quarter. Average portfolio weight of all funds dedicated to INVA is 0.16%, a decrease of 3.02%. Total shares owned by institutions decreased in the last three months by 2.90% to 90,528K shares. The put/call ratio of INVA is 0.18, indicating a bullish outlook.
Innoviva Background Information
(This description is provided by the company.)
Innoviva, Inc. is a healthcare focused asset management company. The Company intends to participate in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva operates in the United States.
See all Innoviva regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.